# ASCENT-1 (NCT07751042)

> Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

No report yet. It can be ordered.

- Drugs tested: STX-003; STX-003 plus pembrolizumab
- Indication: advanced solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07751042
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Strand Therapeutics Inc.
- Conditions: Advanced Solid Tumor
- Interventions: STX-003; KEYTRUDA®
- Enrollment: 220
- Primary outcome: Incidence of TEAEs, SAEs, and DLTs
- Primary outcome: Occurrence of changes from baseline in patients' clinical safety laboratory values and vital signs to assess the safety and tolerability of STX-003.

## Indexed commentary on ASCENT-1 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 8 posts on X
- 1 YouTube video
- 1 podcast episode
- 1 video on X

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=ascent-1-nct07751042

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07751042", "email": "<work email>"}; the inbox owner confirms by the emailed link.
